Skip to Content
Merck
CN

N1165

Pimonidazole

≥98% (HPLC),  2-nitroimidazole hypoxia marker, powder

Synonym(s):

NSC 380540, PD 126675;, Ro 03-8799;, alpha-((2-Nitroimidazol-1-yl)methyl)-1-piperidineethanol;, alpha-[(2-Nitro-1H-imidazol-1-yl)methyl]-1-piperidineethanol

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C11H18N4O3
CAS Number:
70132-50-2
Molecular Weight:
254.29
MDL number:
MFCD00867974
UNSPSC Code:
12352200
PubChem Substance ID:
329818508
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pimonidazole, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >20 mg/mL

storage temp.

2-8°C

SMILES string

OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O

InChI

1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2

InChI key

WVWOOAYQYLJEFD-UHFFFAOYSA-N

Biochem/physiol Actions

Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker.
Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker. Pimonidazole forms adducts with thiol groups in proteins, peptides and amino acids.
Pimonidazole possesses a nitro group at position 2 and an imidazole ring. Pimonidazole undergoes reduction and is activated in hypoxic cells.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000455613
0000455613
0000295515
0000295515
0000139541

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Yong Chen et al.
Disease models & mechanisms, 12(12) (2019-11-11)
Major risk factors for necrotizing enterocolitis (NEC) are formula feeding and prematurity; however, their pathogenic mechanisms are unknown. Here, we found that insufficient arginine/nitric oxide synthesis limits blood flow in the intestinal microvasculature, leading to hypoxia, mucosal damage and NEC
Yuhki Koike et al.
Nature communications, 11(1), 4950-4950 (2020-10-04)
Necrotizing enterocolitis (NEC) is a devastating disease of premature infants with high mortality rate, indicating the need for precision treatment. NEC is characterized by intestinal inflammation and ischemia, as well derangements in intestinal microcirculation. Remote ischemic conditioning (RIC) has emerged
Esther A Kleibeuker et al.
Oncotarget, 7(47), 76613-76627 (2016-10-27)
The extent of tumor oxygenation is an important factor contributing to the efficacy of radiation therapy (RTx). Interestingly, several preclinical studies have shown benefit of combining RTx with drugs that inhibit tumor blood vessel growth, i.e. angiostatic therapy. Recent findings
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service